Viking Therapeutics, Inc. Stock News

Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735 Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, t...

Gross Proceeds to Viking Approximately $575 Million SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its concurrent upsized public offerings of 9,035,714 shares of common stock, at a public offering pric...

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent public offerings of 7,857,143 shares of common stock, at a public offering price of $35.00 per share, and $225.0 million aggregate principa...

SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its intention to offer, subject to market and other conditions, $200.0 million of common stock and $200.0 million aggregate principal amount of convertible senior notes ...

Viking Therapeutics (NASDAQ:VKTX), the clinical-stage biopharmaceutical company, surged over 27% in Tuesday morning trade after reporting trial data showing its obesity drug VK2735 maintained most patients' initial weight loss with less frequent dosing. The drug, a dual agonist targeting the GLP-1 and GIP receptors involved in appetite regulation, demonstrated weight loss maintenance after pati...

Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk's market duopoly.

Viking Therapeutics and Roche both reported positive obesity drug data early Tuesday. Viking stock surged.

Viking Therapeutics ​said ‌on Tuesday its ​experimental ​GLP-1 obesity ⁠drug ​helped patients ​lose 22% of ​their ​body weight after ‌33 ⁠weeks of weekly ​treatment ​in ⁠a maintenance ​study.